Adults in one observational study lost 7.3% of their starting weight on average at 12 weeks [1]. The timing of early changes on a GLP-1 varies with the person and the outcome measured. The study included 115 adults with obesity and no diabetes who took tirzepatide, the active ingredient in Zepbound. Its average does not give an individual three-month target.
What two observational studies found
The 115 adults lost an average of 8.2 kg, or about 18 pounds [1]. The study capped the dose at 5 mg. A second report from the same research group found 8.18% average loss in 51 adults over 12 weeks [3]. The reports do not establish whether the groups overlapped.
What happened after a slow start in SURMOUNT-1
A secondary analysis included 1,545 tirzepatide trial participants [2]. They took at least 75% of assigned doses and had weight measurements at the required visits. By week 12, 1,267 of them, or 82%, had lost at least 5% of starting weight. Of the 278 who had yet to reach 5%, 250 reached it by week 72.
The analysis excluded people who did not meet the dosing and measurement criteria. Its results apply to the selected trial group. Decisions about continuing treatment depend on your response, the dose you tolerate and your prescriber’s assessment.
Why the 72-week results are larger
In the full trial, average weight reductions at week 72 were 15.0%, 19.5% and 20.9% [4]. Those averages came from the 5 mg, 10 mg and 15 mg groups, respectively. The placebo group lost 3.1% on average. The Zepbound label spaces dose increases and lists 5 mg as one maintenance option for weight management [5]. Prescribers consider response and tolerability when selecting a maintenance dose.
How tirzepatide compared with semaglutide
A US study of routine care compared the formulations labeled for type 2 diabetes [6]. The doses covered in a separate three-month comparison illustrate how the regimens can differ. In the US study, the on-treatment weight decrease at three months was 2.4 percentage points greater with tirzepatide. Discontinuation ended follow-up for over half of each treatment group.